http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SE-7610409-L
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba090c867801ab7bccb082f1b694ad25 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 |
filingDate | 1976-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18dbf353b13e134ae97a053c487ee3fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbc2322a99ceb3523de2eb733d5edf08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79258c5d4f565084da5a3cf3505d5bda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbcc296f1dd62923136b93fb71e29d15 |
publicationDate | 1977-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | SE-7610409-L |
titleOfInvention | PHARMACOLOGICALLY ACTIVE ASSOCIATIONS |
abstract | There is disclosed the preparation of compounds of the formula wherein Het' is a 2- or 4-imidazolyl ring optionally substituted by lower alkyl (preferably methyl), halogen (preferably chlorine or bromine), trifluoromethyl or hydroxymethyl, a 2-pyridyl ring optionally substituted by lower alkyl {preferably methyl), lower alkoxy (preferably methoxy), halogen (preferably chlorine or bromine), amino or hydroxy, a 2-thiazolyl ring, a 3-isothiazolyl ring optionally substituted by chlorine or bromine, a 3-(1,2,5) thiadiazolyl ring optionally substituted by chlorine or bromine, or a 2-(5-amino-1,3,4-thiadiazolyl) ring; Z is sulphur or a methylene group; X is oxygen or sulphur; W is methylene, oxygen or sulphur; m and n are such that their sum is from 1 to 4 when W is oxygen or sulphur, or from O to 4 when W is methylene; A is a 1- or 2-naphthyl ring, a 2,3-dihydro-1,4-benzodioxinyl or a 1,3-benzodioxolyl ring, a phenyl ring substituted with one or more lower alkyl, lower alkoxy, halogen, arylalkoxy, hydroxy, alkoxyalkoxy, trifluoromethyl, di(loweralkyl)amino, phenoxy, halophenoxy, alkoxyphenoxy, phenyl, halophenyl or alkoxyphenyl group and when is not a methylene group, A may also be phenyl; and Y3 is hydrogen or lower alkyl. The compounds have both histamine H1-antagonist and H2-antagonist activity. |
priorityDate | 1975-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.